VectivBio Holding AG – NASDAQ:VECT
Market closed
Open in 2 days
VectivBio Holding AG stock price monthly change
+42.02%
month
VectivBio Holding AG stock price quarterly change
+109.68%
quarter
VectivBio Holding AG key metrics
Market Cap | 1.05B |
Enterprise value | 93.95M |
P/E | -4.63 |
EV/Sales | N/A |
EV/EBITDA | -1.08 |
Price/Sales | N/A |
Price/Book | 1.66 |
PEG ratio | 0.18 |
EPS | -3.08 |
Revenue | N/A |
EBITDA | -93.73M |
Income | -93.73M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVectivBio Holding AG stock price history
VectivBio Holding AG stock forecast
VectivBio Holding AG financial statements
| Jun 2021 | 0 | -21.75M | |
|---|---|---|---|
| Sep 2021 | 0 | -21.75M | |
| Dec 2021 | 0 | -21.75M | |
| Dec 2022 | 676K | -28.47M | -4212.76% |
| 2021-12-31 | -1.09353 | -0.80692 |
|---|
| Dec 2021 | 136531000 | 20.53M | 15.04% |
|---|---|---|---|
| Jun 2022 | 178011000 | 36.18M | 20.33% |
| Dec 2022 | 252599000 | 39.23M | 15.53% |
| Apr 2023 | 0 | 0 |
| Jun 2021 | -18.03M | -1.35M | 35.33M |
|---|---|---|---|
| Sep 2021 | -18.03M | -1.35M | 35.33M |
| Dec 2021 | -18.03M | -1.35M | 35.33M |
| Dec 2022 | 54.10M | 3.98M | 69.06M |
VectivBio Holding AG other data
0.02%
-99.98%
of VECT is owned by hedge funds
12
-16
8.56M
-34.14M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2022 19 Apr 2023 | Q4 2022 Earnings Call Transcript |
| Q4 2021 7 Apr 2022 | Q4 2021 Earnings Call Transcript |
Thursday, 29 June 2023 | ||
| Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares | businesswire.com | |
Friday, 16 June 2023 | ||
| Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio | businesswire.com | |
Monday, 12 June 2023 | ||
| Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround | The Motley Fool | |
Monday, 22 May 2023 | ||
| Why Shares of VectivBio Holding Are Up Today | The Motley Fool | |
| VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion | Investors Business Daily | |
| Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion | Barrons | |
| Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion | Market Watch | |
Monday, 17 April 2023 | ||
| VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts | Seeking Alpha |
-
When is VectivBio Holding AG's next earnings date?
Unfortunately, VectivBio Holding AG's (VECT) next earnings date is currently unknown.
-
Does VectivBio Holding AG pay dividends?
No, VectivBio Holding AG does not pay dividends.
-
How much money does VectivBio Holding AG make?
VectivBio Holding AG has a market capitalization of 1.05B. VectivBio Holding AG made a loss 93.74M US dollars in net income (profit) last year or -$0.81 on an earnings per share basis.
-
What is VectivBio Holding AG's stock symbol?
VectivBio Holding AG is traded on the NASDAQ under the ticker symbol "VECT".
-
What is VectivBio Holding AG's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of VectivBio Holding AG?
Shares of VectivBio Holding AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
When VectivBio Holding AG went public?
VectivBio Holding AG is publicly traded company for more then 4 years since IPO on 8 Apr 2021.
-
What is VectivBio Holding AG's official website?
The official website for VectivBio Holding AG is vectivbio.com.
-
How can i contact VectivBio Holding AG?
VectivBio Holding AG can be reached via phone at +41 61551303.
VectivBio Holding AG company profile:
VectivBio Holding AG
vectivbio.comExchange:
NASDAQ
Full time employees:
0
Industry:
Biotechnology
Sector:
Healthcare
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Aeschenvorstadt 36
Basel, 4051
Basel, 4051
CIK: 0001836379
:
CUSIP: H9060V101
